+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Cellink AB (CLNK B) - Financial and Strategic SWOT Analysis Review

  • ID: 5310007
  • SWOT Analysis
  • March 2021
  • 46 pages
  • GlobalData
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Allevi Inc
  • Aspect Biosystems Ltd
  • Cyfuse Biomedical KK
  • Envisiontec GmbH
  • Materialise NV
  • n3D Biosciences Inc
  • MORE
Cellink AB (CLNK B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Cellink AB (Cellink) develops and commercializes bioprinting technologies which enable researchers to print three dimensional (3D) human organs and tissues. The company’s product portfolio encompasses bioprinters which enable bioprinting of human tissues and tissue models for 3D culture in advanced research; and bioink, a biomaterial innovation that allows researchers to develop and grow 3D human cells to grow as they do in the natural human body environment. Cellink caters to research institutions, pharmaceutical, biopharmaceutical, automotive, and cosmetic companies. The company sells its products through direct sales force in the US and Sweden and through an extensive network of distributors in Europe (excluding Sweden), and Asia-Pacific. It operates a subsidiary in the US. Cellink AB is headquartered in Goteborg, Sweden.

Cellink AB Key Recent Developments

Mar 15, 2021: Cellink launches the Bio Mdx Series, a scaled-up revolution in biomedical manufacturing
Mar 11, 2021: Cellink announces an offering of Senior Unsecured Convertible Bonds convertible into Class B shares and a Class B share issue in an expected amount of SEK 2.75 billion
Feb 08, 2021: CELLINK announce distribution agreement including new products for Single-Cell RNA Sequencing and NGS Library Preparation
Jan 28, 2021: CELLINK announces third year extension of collaboration with a global biopharmaceutical company for drug discovery
Nov 27, 2020: CELLINK welcomes new scientific advisor Professor Robert Langer from MIT and co-founder of Moderna

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Allevi Inc
  • Aspect Biosystems Ltd
  • Cyfuse Biomedical KK
  • Envisiontec GmbH
  • Materialise NV
  • n3D Biosciences Inc
  • MORE
Section 1 - About the Company
  • Cellink AB - Key Facts
  • Cellink AB - Key Employees
  • Cellink AB - Key Employee Biographies
  • Cellink AB - Major Products and Services
  • Cellink AB - History
  • Cellink AB - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • Cellink AB - Business Description
  • R&D Overview
  • Cellink AB - Corporate Strategy
  • Cellink AB - SWOT Analysis
  • SWOT Analysis - Overview
  • Cellink AB - Strengths
  • Cellink AB - Weaknesses
  • Cellink AB - Opportunities
  • Cellink AB - Threats
  • Cellink AB - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • Cellink AB, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
  • Cellink AB, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
  • Cellink AB, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • Mar 15, 2021: Cellink launches the Bio Mdx Series, a scaled-up revolution in biomedical manufacturing
  • Mar 11, 2021: Cellink announces an offering of Senior Unsecured Convertible Bonds convertible into Class B shares and a Class B share issue in an expected amount of SEK 2.75 billion
  • Feb 08, 2021: CELLINK announce distribution agreement including new products for Single-Cell RNA Sequencing and NGS Library Preparation
  • Jan 28, 2021: CELLINK announces third year extension of collaboration with a global biopharmaceutical company for drug discovery
  • Nov 27, 2020: CELLINK welcomes new scientific advisor Professor Robert Langer from MIT and co-founder of Moderna
  • Oct 22, 2020: Cellink: Strong organic growth and important strategic acquisition under continued challenging conditions
  • Oct 21, 2020: CELLINK launches C.WASH, an innovative liquid handling system for automated media change in micro-well plates
  • Aug 28, 2020: CELLINK welcomes new scientific advisor Professor Ido Amit from the Weizmann Institute of Science
  • Jul 14, 2020: CELLINK and Kugelmeiers announce strategic partnership for 3D printing cell spheroids
  • Jul 09, 2020: Cellink - Q3 19/20: Continued growth and main market listing during an ongoing pandemic
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Cellink AB, Key Facts
  • Cellink AB, Key Employees
  • Cellink AB, Key Employee Biographies
  • Cellink AB, Major Products and Services
  • Cellink AB, History
  • Cellink AB, Other Locations
  • Cellink AB, Subsidiaries
  • Cellink AB, Key Competitors
  • Cellink AB, Ratios based on current share price
  • Cellink AB, Annual Ratios
  • Cellink AB, Interim Ratios
  • Cellink AB, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
  • Cellink AB, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
  • Cellink AB, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • Cellink AB, Performance Chart (2016 - 2020)
  • Cellink AB, Ratio Charts
  • Cellink AB, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
  • Cellink AB, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021
Note: Product cover images may vary from those shown
3 of 3
  • Organovo Holdings Inc
  • n3D Biosciences Inc
  • Materialise NV
  • Envisiontec GmbH
  • Cyfuse Biomedical KK
  • Aspect Biosystems Ltd
  • Allevi Inc
Note: Product cover images may vary from those shown
Adroll
adroll